Mirum Pharmaceuticals, Inc. Operating Income Loss

• Mirum Pharmaceuticals, Inc. showed an increase of +74.7% in Operating Income Loss from 2024 to 2025.
• This data is from Mirum Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Mirum Pharmaceuticals, Inc.'s Operating Income Loss has grown by 59.6%.
• Historical annual values: Fiscal year 2025: -$22.14 million | Fiscal year 2024: -$87.61 million | Fiscal year 2023: -$109.15 million | Fiscal year 2022: -$131.22 million | Fiscal year 2021: -$173.41 million | Fiscal year 2020: -$104.30 million | Fiscal year 2019: -$54.74 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026